FOX04-DRI

• 10mg lyophilized peptide

FOXO4-DRI works by interfering with the binding between FOXO4 (a transcription factor enriched in senescent cells) and p53, the protein that prevents damaged cells from self-destructing. In research models, this leads to: This makes FOXO4-DRI a major molecule of interest in senolytic, longevity, and regenerative studies.

• Senolytic action that disrupts the FOXO4 p53 interaction, selectively inducing apoptosis in senescent cells while sparing healthy cells.
• Cellular rejuvenation signaling by clearing senescent cells, supporting tissue regeneration, reduced inflammation signals, and improved organ function endpoints.
• Anti aging effects that may reduce age related cellular dysfunction, potentially supporting lifespan and vitality related outcomes in experimental models.

FOXO4-DRI is commonly studied for

• Longevity and anti aging interest through clearance of damaged senescent cells that contribute to age related decline.
• Inflammation reduction signals through reduction of inflammatory markers linked to chronic disease and tissue degeneration.
• Tissue repair and regeneration support through improved organ function and tissue homeostasis, allowing healthy cells to proliferate.
• Cognitive and neurological support interest by reducing senescent cell accumulation in the brain, relevant to neurodegenerative disease research models.

Early research descriptions characterize FOXO4-DRI as well tolerated, with minimal side effects observed in animal models. Possible short term fatigue or mild discomfort has been noted post administration in some discussions, potentially as senescent cells are cleared. Further human studies are required to confirm long term safety and efficacy, and medical guidance is appropriate before any real world use.

No negative interactions have been documented between FOXO4-DRI and other compounds in controlled preclinical settings.